Parmax Pharma Ltd.

As of June 30, 2026, Parmax Pharma Ltd. carries a market capitalization of 292.18M, placing it among publicly traded companies globally. Its enterprise value stands at 292.18M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Parmax Pharma Ltd. has 3.74M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.59 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 292.18M versus a market cap of 292.18M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

Over the twelve months ended June 30, 2026, Parmax Pharma Ltd. recorded an income tax benefit of -16.87M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -28.82M and -11.95M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 19, 2026, Parmax Pharma Ltd.'s stock has gained approximately 296.05% over the past 52 weeks. The 50-day moving average sits at 107.65, while the 200-day moving average is 53.42.

Over the twelve months ended June 30, 2026, Parmax Pharma Ltd. generated 183.90M in revenue and converted that into -11.95M in net income, yielding earnings per share of -3.20. EBITDA reached -25.09M, while operating income came in at -37.60M.

Over the twelve months ended June 30, 2026, Parmax Pharma Ltd. posted a gross margin of 20.44, reflecting its pricing power and cost economics. The operating margin of -20.45 and net profit margin of -6.50 provide insight into operational efficiency.